Procedural sedation with intranasal dexmedetomidine for radiation treatment.
Phase 4
- Conditions
- Health Condition 1: - Health Condition 2: C729- Malignant neoplasm of central nervous system, unspecified
- Registration Number
- CTRI/2020/09/027579
- Lead Sponsor
- ACHARYA HARIHAR POST GRADUATE INSTITUTE OF CANCER
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
ASA 1to 3
Exclusion Criteria
Children with upper respiratory tract infection, airway obstructive conditions, congenital heart disease, neurological or mental abnormality, any other systemic disease other than cancer, on hepatic enzyme inducing drugs or allergy to study drug and refusal to participate
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of intranasal dexmedetomidine in pediatric sedation for CNS malignancies?
How does intranasal dexmedetomidine compare to oral midazolam and ketamine in sedation efficacy for CNS tumor radiation?
What biomarkers predict response to intranasal dexmedetomidine in children with central nervous system cancers?
What are the adverse event profiles of intranasal dexmedetomidine versus midazolam-ketamine combinations in pediatric oncology?
Are there alternative sedation regimens for CNS tumor radiation using alpha-2 adrenergic agonists or other drug classes?